Molecular Hydrogen (H₂) for Parkinson's Disease

Also known as: H2 therapy, Hydrogen water, Hydrogen gas inhalation

H₂ selectively neutralizes hydroxyl radicals in dopaminergic neurons without disrupting dopamine signaling.

Mechanism of Action

H₂ scavenges •OH produced by iron-catalyzed Fenton reactions in dopamine metabolism. It protects Complex I from oxidative inhibition, reduces 6-OHDA-induced dopaminergic damage, and activates Nrf2-dependent antioxidant defense in the substantia nigra.

General mechanism: Selective antioxidant gas. Scavenges •OH and ONOO⁻ while preserving signaling ROS. Nrf2 activator, NF-κB inhibitor.

Current Evidence

Randomized trial (Yoritaka et al., 2013) showed hydrogen water improved UPDRS scores in PD patients. Follow-up studies support safety. Larger confirmatory trials planned.

Clinical Status: Phase II trials for PD. Hydrogen water showed UPDRS improvement.

Safety Profile

Extremely safe. No toxicity at therapeutic concentrations. Non-flammable at <4% concentration. No side effects reported.

Key Research Questions

View glossary entry →

← Back to Parkinson's Disease Research